Revenue: As of FY2026 Q1, the actual value is USD 162.09 K.EPS: As of FY2026 Q1, the actual value is USD -1.28.EBIT: As of FY2026 Q1, the actual value is USD -2.105 M.60 Degrees Pharmaceuticals, Inc. operates as a single identifiable segment focused on developing and marketing new medicines for infectious diseases .<h4>Segment Revenue</h4>Product revenues, net of discounts and rebates, for the three months ended March 31, 2026, were $162,092, representing a -0.89% decrease from $163,552 in the prior-year period, primarily due to returns associated with expiring product lots . In Q1 2026, the U.S. pharmaceutical distributor accounted for 90% of total net product sales of Arakoda, while Kodatef sales to the Australian distributor accounted for 10% . Sales volume of Arakoda (16-ct box equivalents) decreased by 19% from 1,579 boxes in Q1 2025 to 1,276 boxes in Q1 2026 . Kodatef sales to Biocelect in Australia were $15,470 in Q1 2026, up from $12,066 in Q1 2025, though sales volume decreased by 8% to 354 boxes . Arakoda sales volume in Europe, through Scandinavian Biopharma, increased by 5% to 77 boxes in Q1 2026 . Research revenues were $0 for the three months ended March 31, 2026, a -100.00% decrease from $92,731 in the prior-year period, as the USAMMDA contract was fully utilized by the end of 2025 .<h4>Operational Metrics</h4>Cost of revenues increased by 16.98% to $85,715 for the three months ended March 31, 2026, from $73,272 in the prior-year period, mainly due to higher quarterly storage costs . Gross profit decreased by -15.40% to $76,377 in Q1 2026 from $90,280 in Q1 2025, with gross margin declining from 55.20% to 47.12% . Total operating expenses increased by 3.70% to $2,171,338 in Q1 2026 from $2,093,949 in Q1 2025 . Research and development costs decreased by -24.10% to $281,464, primarily due to the absence of packaging validation costs incurred in the prior year . General and administrative expenses rose by 9.68% to $1,889,874, driven by higher sales, advertising, and promotion expenses, and increased audit, legal, and professional fees . Loss from operations for the three months ended March 31, 2026, was - $2,094,961, compared to - $1,910,938 in the same period of 2025 . Net loss attributable to 60 Degrees Pharmaceuticals, Inc. was - $2,089,214 for the three months ended March 31, 2026, compared to - $1,876,549 in the prior-year period .<h4>Cash Flow</h4>Net cash used in operating activities increased by 71.63% to - $2,741,559 for the three months ended March 31, 2026, from - $1,597,366 in the prior-year period, driven by higher general and administrative expenses and increased vendor prepayments for API production . Net cash provided by investing activities was $1,193,560, a decrease from $1,702,518 in the prior-year period, mainly due to proceeds from maturities of short-term investments . Net cash provided by financing activities significantly increased by 98.58% to $3,369,752, primarily due to higher net proceeds from At-the-Market (ATM) offerings .<h4>Outlook and Strategy</h4>60 Degrees Pharmaceuticals, Inc. estimates it will have sufficient funds to operate through mid-September 2026, assuming no additional capital raises, based on current internal projections and recent proceeds from public offerings . However, the company does not have sufficient cash and cash equivalents to fund its operating plan for the next 12 months, raising substantial doubt about its ability to continue as a going concern . Management plans to fund operations through third-party and related-party debt/advances, private placement of restricted securities, and subsequent stock offerings to achieve profitability or a business combination .

60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 162.09 K